Successful Reintroduction of Lamotrigine after Initial Rash
International Journal of Epilepsy · 01.08.2026 · 12 (S 01 S 01) · S3-S35
DOI: 10.1055/s-0046-1825955 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Epilepsy, erschienen am 01.08.2026. Verfasst von Dhananjay Duberkar und 1 weiteren Autor:innen.
Abstract (Originalsprache)
The most serious concern with lamotrigine (LTG) treatment is a hypersensitivity reaction presenting as a rash. Despite this, LTG is an antiepileptic drug (AED) with more favorable efficacy/tolerability ratio compared with the other new as well as old AEDs. We present two cases where LTG was reintroduced with a slower titration after development of a rash. Successful reintroduction is possible when a very slow, low-dose escalation regimen is used. Publication History Article published online: 15 July 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Private Limited A-13A, Graphix Tower 1, 6th floor, Sector 62, Noida 201309, Uttar Pradesh, India
Zitieren
APA
Duberkar, D., & Jagtap, S. (2026). Successful Reintroduction of Lamotrigine after Initial Rash. International Journal of Epilepsy, 12(S 01 S 01), S3-S35. https://doi.org/10.1055/s-0046-1825955
Vancouver
Duberkar D, Jagtap S. Successful Reintroduction of Lamotrigine after Initial Rash. International Journal of Epilepsy. 2026;12(S 01 S 01):S3-S35. doi:10.1055/s-0046-1825955
BibTeX
@article{Duberkar2026,
author = {Duberkar, Dhananjay and Jagtap, Sujit},
title = {Successful Reintroduction of Lamotrigine after Initial Rash},
journal = {International Journal of Epilepsy},
year = {2026},
volume = {12},
number = {S 01 S 01},
pages = {S3--S35},
doi = {10.1055/s-0046-1825955}
}
EUVIMED